SQZ vs. FRTX, KRBP, NSTGQ, PALI, TCBP, TCON, GMDAQ, ELOX, FNCH, and WINT
Should you be buying SQZ Biotechnologies stock or one of its competitors? The main competitors of SQZ Biotechnologies include Fresh Tracks Therapeutics (FRTX), Kiromic BioPharma (KRBP), NanoString Technologies (NSTGQ), Palisade Bio (PALI), TC Biopharm (TCBP), TRACON Pharmaceuticals (TCON), Gamida Cell (GMDAQ), Eloxx Pharmaceuticals (ELOX), Finch Therapeutics Group (FNCH), and Windtree Therapeutics (WINT). These companies are all part of the "biological products, except diagnostic" industry.
Fresh Tracks Therapeutics (NASDAQ:FRTX) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Fresh Tracks Therapeutics has higher earnings, but lower revenue than SQZ Biotechnologies. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Fresh Tracks Therapeutics has a net margin of -91.29% compared to Fresh Tracks Therapeutics' net margin of -369.96%. SQZ Biotechnologies' return on equity of -60.83% beat Fresh Tracks Therapeutics' return on equity.
SQZ Biotechnologies received 10 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave SQZ Biotechnologies an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote.
Fresh Tracks Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.
In the previous week, Fresh Tracks Therapeutics had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for Fresh Tracks Therapeutics and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 0.71 beat Fresh Tracks Therapeutics' score of 0.00 indicating that Fresh Tracks Therapeutics is being referred to more favorably in the media.
Summary
Fresh Tracks Therapeutics beats SQZ Biotechnologies on 8 of the 15 factors compared between the two stocks.
Get SQZ Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SQZ Biotechnologies Competitors List
Related Companies and Tools
